Body fluid biomarkers in Alzheimer’s disease

Huan Lu, Xi-Chen Zhu, Teng Jiang, Jin-Tai Yu, Lan Tan

Department of Neurology, Qingdao Municipal Hospital, Nanjing Medical University, Nanjing 210029, China; Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China; Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao 266001, China; Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94158, USA

Correspondence to: Jin-Tai Yu. Department of Neurology, University of California, 675 Nelson Rising Lane, Suite 190, Box 1207, San Francisco, CA 94158, USA. Email: yu-jintai@163.com or jintai.yu@ucsf.edu; Dr Lan Tan. Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No. 5 Donghai Middle Road, Qingdao 266071, China. Email: dr.tanlan@163.com.

Abstract: A heterogeneous and slowly progressive disease with extracellular amyloid-β (Aβ) deposits and intracellular hyperphosphorylated tau protein aggregates, Alzheimer’s disease (AD) is already a hard nut to crack, featured with cognitive decline and memory lapse. Body fluid biomarkers are proved to be useful in exploring further study of AD, might benefit for a full comprehension of the etiopathogenesis, an improved precision of the prognosis and diagnosis, and a positive response of treatments. The cerebrospinal fluid biomarkers Aβ, total tau, and hyperphosphorylated tau reflect the main pathologic changes of AD. We also review data from several novel biomarkers, such as, β-site APP cleaving enzyme 1, soluble amyloid precursor proteins α and β, soluble Aβ oligomers and so on, which are associated with the occurrence and deterioration of this disease and couldn’t be ignored. The rationale for the clinical use of those biomarkers, the challenges faced with and the properties of the most appropriate biomarkers are also summarized in the paper. We aim to find several ideal biomarkers to improve the diagnosis and optimize the treatment respectively.

Keywords: Alzheimer’s disease (AD); biomarkers; amyloid-β (Aβ); tau protein; β-site APP cleaving enzyme 1 (BACE1)

Submitted Feb 03, 2015. Accepted for publication Feb 03, 2015.
doi: 10.3978/j.issn.2305-5839.2015.02.13
View this article at: http://dx.doi.org/10.3978/j.issn.2305-5839.2015.02.13

Introduction

Dementia is a major global cause of disability and dependency. As of 2013, an estimated 44.4 million people had dementia worldwide; by 2030, this number will almost double to an estimated 75.6 million, and then almost double again to 135.5 million in 2050. Much of the increase will be in developing countries with the fastest growth in the elderly population. People with dementia living in developing countries have accounted for already 62% of all patients, but by 2050 this will rise to 71%. The total estimated global societal direct and indirect cost of dementia in 2010 was $604 billion (http://www.alz.co.uk/research/statistics). That will be a big challenge, and most of health care systems will be unable to deal with this development.

Alzheimer’s disease (AD), living in the global the third lethal disease (1), is a complex progressive neurodegenerative disease that is characterized by an irreversible cognitive functions decline, a loss of memory and a high degree of heterogeneity in clinical and radiological. Biomarkers can be defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention” (2). Therefore, biomarkers that reliably capture the different aspects of disease heterogeneity are needed, and might help to better understand AD aetiopathogenesis, diagnosis, and prognosis, to predict response outcome to treatments, and to develop new treatments.

The AD biomarker research field is always very active during several decades. The most famous theory, the “amyloid cascade hypothesis” for AD (3) posits that an imbalance between the production and clearance of β-amyloid (Aβ) is the initiating event in disease pathogenesis, ultimately
leading to tauopathy, neurodegeneration, and cognitive and behavioral changes. Aβ was proposed as the initiating factor in the disease process which is correlated with β-amyloid precursor protein (APP) metabolism, Aβ generation and tau protein homeostasis. Mayeux and Stern (4) found that the lesions associated with the disease could begin decades prior to the emergence of clinical symptoms. Disease-modifying drugs will probably be more effective in the earlier stages of the disease, because in advanced AD patients plaque and tangle load as well as neurodegeneration will become highly severe (5-7). Thus, to find some useful early biomarkers is crucial, which might help to improve the diagnosis of AD especially prodromal or preclinical AD. It will most likely slow down disease progression and cut the morbidity and mortality by the early intervention. In spite of a substantial number of candidate biomarkers proposed and theories established, few biomarkers can meet the full needs of clinically useful biomarkers, which lead to another important challenge. In this review, we focus on some established biomarkers evaluated in several different studies and an assortment of novel biomarkers in AD, as well as their potential roles in clinical trials.

**Aβ isoforms**

Some of this category of biomarkers such as, cerebrospinal fluid (CSF) Aβ42 and Aβ40 isoforms, are repeatedly validated by different groups in an independent cohort of patients with AD, and even are currently used in AD clinical practice. In the wake of the development of so-called omics technologies which have enabled the identification of novel biomarkers in an unbiased and semiquantitative way (8), biomarker discovery has been strongly boosted in the past decades. Simultaneously, an assortment of technological approaches such as two-dimensional polyacrylamide gel electrophoresis and mass spectrometer analysis are employed in the exploration of biomarkers. Human beings have been able to employ a great diversity of novel Aβ isoforms to investigate the secrets of AD. Given β-site APP cleaving enzyme 1 (BACE1) and soluble amyloid precursor proteins α and β (sAPPα/sAPPβ) significantly associated with the metabolism of APP and the production of Aβ; much attentions were paid to both of them.

**Cerebrospinal fluid Aβ isoforms**

The discovery that playing a central role in the pathogenesis of AD, Aβ is derived from the transmembrane APP by proteolytic processing during normal cell metabolism and is secreted into the CSF served as the foundation for Aβ biomarker development. However, mechanisms associated with Aβ generation are not fully known. The most important Aβ isoform is Aβ42, which is a 42 amino-acid long and aggregation-prone protein. Many studies found that the levels of CSF Aβ42 in AD is reduced to approximately half of control levels by using several different enzyme linked immunosorbert assay (ELISA) methods (9,10). In recently study demonstrated that the decrease of Aβ42 concentrations in the CSF was associated with PSEN mutations that cause AD (11). Another study came to the opposite conclusion that mutation carriers had higher CSF Aβ42 levels than non-carriers (12). Low CSF Aβ42 levels reflect the decreased clearance and the increased deposition of Aβ42 in the brain, however, this is not absolutely specific for AD and is also observed in patients with dementia with Lewy bodies.

CSF Aβ40 is another important biomarker in AD. The levels of CSF Aβ40 diminish with increased age (13), and decrease significantly in AD subjects than those with mild cognitive impairment (MCI) (14). But no significant difference was found among AD participants, nondemented controls, and patients with non-AD dementia (15).

Further discovery about other Aβ isoforms found the CSF Aβ17-40/Aβ11-40 ratio significantly higher in patients with CDR-SB ≤1.5 (Cognitive Dementia Rating-Sum of Boxes score) than in controls, may become a novel biomarker to discriminate between them (16). The assessment of Aβ17 may increase the diagnostic performance of blood-based Aβ tests which might be developed into minimally invasive first-step screening tests for people with increased risk for AD (17). These conclusions needed to be confirmed in other larger clinical independent studies.

**Aβ oligomers**

Exactly as deposited fibrillary Aβ, soluble Aβ oligomers, assemblies ranging from dimers to 24-mers, can also induce the formation of tau neurofibrillary pathology (18,19), although it is still unclear in the literature whether Aβ pathology is responsible for tau pathology in AD. Multiple lines of evidence suggested that Aβ oligomers may be more toxic than fibrillar Aβ aggregates (20,21). Accumulating evidences from studies of transgenic mouse models demonstrated that AD brain-derived and synthetically prepared Aβ oligomers can cause early synaptic toxicity (22), long-term potentiation (LTP) deficits, tau phosphorylation and neurofibrillary tangles (23). Specific cognitive deficits express in animals (Zebrafish
Embryo) injected with Aβ peptide correlated with Aβ peptide accumulation and memory impairment in rodent, as suggested by Nery et al. (24). In the recently study shows a significant 3-to-5-fold increase in Aβ oligomers in human AD CSF compared with comparably aged controls (25). Further, oligomer levels increase as MMSE score drops (25). Of course, with a very low CSF level, probably less than 1% of total Aβ levels, it is very difficult to quantify the CSF level of Aβ oligomers in a reliable manner. However, Santos et al. (26) thought there was a negative correlation between the levels of Aβ oligomers and cognitive status measured by the Mini-Mental Status Exam score (r=-0.65; P=0.013) in AD patients. The detection of Aβ-oligomers using flow cytometry analysis suggests a potential use for assessing disease stage in AD individuals. Another study discovered no difference the CSF level of Aβ oligomers between AD and control groups, indicating levels of small oligomers unsuitable as biomarkers for AD (27). The reason may be the levels of Aβ oligomers elevating in human and mouse brains are very low or absent in CSF (28). The increased levels of Aβ oligomers are positive association with age and levels of total tau in cognitively normal older adults, and elevated levels of both oligomers (Aβ*56 and Aβ trimers) were found in cognitively normal subjects indicating impending AD (29). It is difficult to measure minute amounts of Aβ oligomers in CSF samples, thus, reliable methods to access Aβ oligomers are urgently needed. The onset and progression of AD associated specific technique to detect Aβ oligomers would be a valuable tool in AD diagnostics.

**Plasma Aβ**

Since plasma and serum is noninvasive and more easily available than CSF from lumbar puncture, to find reliable plasma and serum biomarkers for AD is with great promise. With the development of measurement methodology and efforts from generation to generation, several novel blood biomarkers have been proposed, although verification and validation in independent studies remains to be clearly further established.

Aβ as a driving force in AD is very important in the pathogenesis of senile plaques, therefore plasma Aβ suffered from widespread concerns and has been studied extensively in relation to AD diagnosis and risk. However, studies of plasma Aβ have been contradictory and some cross-sectional analyses have reported higher Aβ1–42 levels (30), higher Aβ1–40 levels (30,31), while others have found lower levels of Aβ1–42 (32,33) as well as no significant differences between AD patients and controls. Some studies found also that a low ratio of Aβ42 to Aβ40 (AβR) (32,33) predicted future AD while others report an elevated ratio or no associations in the group with incipient AD compared with subjects that didn’t develop AD. Some cohort studies found higher plasma concentrations of Aβ1–40 (34,35), higher plasma concentrations of Aβ1–42 (34,36), high AβR (30) or low AβR (35-37) were associated with risk for AD. But other cohort studies suggested lower plasma Aβ1–40 levels (38), lower plasma Aβ1–42 levels predicted incident AD and were not significantly associated with AD incidence. In one study, a decrease in Aβ1–40 in early stages and an increase in AβR were associated with a worse cognitive performance among AD patients (39). Another study found that high plasma concentrations of Aβ42 was associated with a faster rate of cognitive decline among AD patients (40). Matsuoka et al. (41) got a tendentious conclusion that AβR is more strongly important to the pathophysiologic process of AD than absolute levels of the peptides in genetically susceptible populations. However, it has been very hard to reproduce above findings in independent studies (42), and this pre-eminent unsolved medical problem remains to explore.

**BACE1**

Chemical property of BACE1 is membrane-associated aspartic protease 2. Aβ peptide is produced by proteolytic cleavage of APP by two different enzymes, β-secretase and γ-secretase, one of which is the protein encoded by the BACE1 gene. The encoded protein, a member of the peptidase A1 protein family, is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi, and its official full name is β-site APP cleaving enzyme-1.

Unlikely CSF Tau and Aβ, CSF BACE1 and soluble amyloid precursor proteins α and β are without consistent patterns in AD participants. Numerous researchers have investigated the levels of CSF BACE1 activity in patients with MCI and AD compared with age-matched controls, but the results are not univocal. Two studies found that patients with AD had increased Plasma BACE1 activity (43) and CSF BACE1 activity (44) compared with non-demented controls. Similarly, significant elevation of BACE1 levels and activity in CSF in patients with MCI due to AD compared with controls (45), and a higher elevated BACE1 activity in patients with MCI but not with AD when comparing with health controls (46) were demonstrated, respectively. Mulder et al. (47) found that no correlation
between BACE1 activity and Aβ42, and subsequent large study suggested no significant differences in BACE1 activity between AD patients and controls (48).

However, when patients with a pathologic profile of the core AD biomarkers were compared with controls with a normal biomarker pattern, a significant elevation of BACE1 activity was found in the patient group. The MCI patients contributed the most to this elevation. When the AD patients were stratified into mild and moderate-severe AD, an increased BACE1 activity could be seen in the group with mild AD compared the more advanced AD patients and controls. These studies demonstrate that the levels or activity of BACE1 may be mildly elevated in the early stages of AD, which could become a useful biomarker to predict incipient AD.

**sAPPα/sAPPβ**

Cleavage of APP by α-secretase generates soluble N-terminal fragments of 100-130 kDa (sAPPα) and an 83 amino acid, membrane associated C-terminal fragment, which consists of the C-terminal portion of Aβ, and APP cytosolic domain. The alternative, amyloidogenic pathway involves cleavage of APP by β-secretase at the amino terminus of Aβ to release the soluble N-terminal fragment, sAPPβ, followed by processing of the remaining 99 amino acid membrane tethered C-terminal fragment by γ-secretase to release Aβ.

The CSF concentration of sAPPα and sAPPβ correlates very well with AD patients as well as controls (45). Patients with AD had increased sAPPβ and sAPPα compared with non-demented controls (43). However, no difference was showed in the levels of these biomarkers between AD patients and controls in other studies (45,48). The higher concentration of sAPPβ was found in MCI patients compared with controls (49), and MCI patients with incipient AD had higher levels of sAPPβ than patients without (50). However, Hertze et al. (51) found no differences in sAPP levels in MCI patients that upon follow up advanced AD compared with stable MCIs or patients with other dementias. Compared patients with MCI or dementia that had a pathologic core CSF AD biomarker profile with controls with a normal profile, several studies found that the former group had significant elevation of sAPPα and sAPPβ levels, but there were large overlaps between the groups (52,53). We have mountains of work to study the diagnosis value of sAPPα and sAPPβ.

According to the study by Lewczuk et al. (52), there are two well-known and one possible risk factors for AD, the effects of age, the presence of the APOEε4 allele and the integrity of the blood-CSF barrier, which may be associated with the CSF concentrations of sAPPα and sAPPβ. To further unravel the story of this newly identified, larger sample sizes, better measurement and study designs and more case-control studies are needed.

**Total tau (T-tau) and phosphorylated tau (P-tau) protein**

In addition to presenting morphologically with senile plaques, primarily made of extracellular Aβ deposits, AD suffers also from neurofibrillary tangles, another validated histopathological change, which consist of intracellular aggregates of hyperphosphorylated tau protein. A microtubule associated protein, tau participates in the microtubule stabilization and organization system which regulates cellular morphogenesis, cytoskeleton functionality and axonal transport. It is comprehensible that high levels of tau in CSF of AD patients can reflect the intensity of neuronal damage and degeneration in the brain.

All of several isoforms of the tau protein in CSF contain a large number of serine and threonine phosphorylation sites (54,55), which makes hyperphosphorylation possible. The most commonly used measurement method for T-tau and P-tau is the ELISA, for T-tau based on monoclonal antibodies that detect all isoforms of tau independently of phosphorylation state and for P-tau using antibodies that are specific for phosphorylation at either threonine181 (P-Tau181) or threonine231 (P-Tau231). P-tau231 are useful for distinguishing AD and frontotemporal dementia, and p-tau181 can enhance classification between AD and dementia with Lewy bodies (56). Numerous studies have used this assay, and consistently report a prominent increase of CSF T-tau and P-tau in AD against control levels (9). The immunoassays used to analyze tau levels in blood have also been established (56). Tau is rapidly released into the bloodstream after hypoxic brain injury following cardiac arrest, but effectively (within 24 hours) cleared in patients with good neurological outcome (57). In a recent study supporting this view found that plasma tau make no difference between AD and normal control group (31). Another study found significantly higher plasma tau levels in patients with MCI or early AD compared with health elders (58). In view of tau reflecting intracellular impairment in neurocyte, it is necessary to further study to
tau proteins including varied forms or locations.

Combination of tau and Aβ as biomarkers

The diagnostic accuracy for the combination of decreased Aβ42 and increased T-tau and P-tau has a higher sensitivity and specificity of more than 85% in differentiating AD from healthy controls than for any biomarker alone (59,60). The addition of P-tau to Aβ42 and T-tau further increases specificity for AD (60). Tau and Aβ as Biomarkers are two main types of aberrant proteinaceous aggregates found associated to AD. Along with the development of the AD biomarkers, specifically the Aβ/tau ratio, studies may easier identify or distinguish patients at higher risk for cognitive changes from healthy controls. Xie et al. (61) gave evidence in his clinical trial that Preoperative CSF Aβ/tau ratio is associated with neuropathogenesis of postoperative cognitive dysfunction. In a recently study, Xie et al. (62) emphasized once again lower CSF Aβ/Tau ratio could be associated with postoperative delirium or postoperative cognitive change. Notably, this combination of CSF tau and Aβ biomarker changes may predict the conversion from mild cognitive impairment (MCI) subjects to AD patients. However, it is essential to standardize the measurement methodology for CSF Aβ42 and tau concentrations before the utility of combination for diagnosis of AD is established. For example, a multiparameter assay for simultaneous quantification of these CSF biomarkers is based on the LuminexTM xMAP technology whose diagnostic performance has been good (63).

MicroRNA (miRNA)

The miRNAs are small double-stranded, non-coding RNA molecules of 21–25 nucleotides that mainly bind to 3’untranslated region (3’UTR) of target mRNAs and fine-tune gene expression at posttranscriptional level. The imperfect sequence complementarity between a miRNA and its target mRNA enables a single miRNA to regulate many mRNAs (64). Kong et al. (65) found the dysregulation of miRNAs could interrupt the metabolism of amino acids in the brain so as to accelerate the pathological process of AD by investigating miRNA expression profile of adult-onset drosophila AD model.

Accumulating data focused on the role of miRNA in APP and Aβ metabolism. The level of miR-107, regulating the expression of BACE1, is significantly lower in AD (66). Another study identified 11 microRNAs, including miR-107 and miR-26b, may be involved in cholesterol induced AD-like pathology (67). Liu et al. (68) found that the levels of miR-135a, repressing expression and activity of BACE-1, miR-200b and -429, suppressing expression of APP, in the serum or CSF of AD groups were significantly lower than that of control groups. The decreased miR-384 expression was showed in CSF and serum of Patients with MCI and dementia of Alzheimer’s type compared with the controls (69). The levels of miR-146a were significantly lower than age-matched nondemented control subjects in CSF of AD patients (70). Hébert et al. (71) found that expression levels of miRNA-29a/b-1 cluster are reduced in the cortexes of sporadic AD patients, associated with a 2- to 5-fold increase in the level of BACE1 protein. Several studies found some miRNAs such as, Let-7 (72), miR-146a (70) and miR-132 (73), miR-29a/b (74,75) could lead to the spread of CNS damage by inducing neurocyte inflammation or apoptosis (Table 1). Other instances the roles of miRNA in AD include miR-124 regulating the APP mRNA alternative splicing, MiR-101, -520c, -147, -16, -20a, -644 and -153 targeting 3’UTR of APP mRNA, MiR-107, -29a/b1/c, -9, -328 and -298 regulating the expression of BACE1, and miR-384 suppressing the mRNA and protein expression of both APP and BACE-1.

In conclusion, such alterations in miRNA levels would play an important part in the diagnosis and/or targeted treatment of AD in human patients. In the future more robust and invasion-free diagnostic methodology in complement with traditional methods involving collection of CSF, plasma or serum will be published.

Apolipoprotein E (APOE)

Convincing evidence suggests that an increase in total Aβ production, an increase in the ratio of Aβ42 to Aβ40, or generation of a mutant form of Aβ with greater amyloidogenic propensity are the main mechanisms for the rare early-onset forms of autosomal-dominant familial AD, but these are probably not the major pathogenic mechanisms underlying the more common late-onset AD. APOE genotype has been reported as the strongest genetic risk factor for late-onset AD, with the ε4 allele being an AD risk factor and the ε2 allele being protective. Many studies found the APOE is able to influence the transport and metabolism of the Aβ, and the interaction of APOE with Aβ plays an important role in AD pathogenesis. However, Zimmermann et al. found the opposite conclusion by measure plasma levels of Aβ proteins in young healthy
Table 1 The dysregulation of miRNAs in neurodegeneration of Alzheimer disease

<table>
<thead>
<tr>
<th>Category</th>
<th>Signalling passway</th>
<th>Comment</th>
<th>AD CSF levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-34a</td>
<td>Tau proteins</td>
<td>Influence the expression of Tau (75)</td>
<td>Plasma and CSF decreased (75)</td>
</tr>
<tr>
<td>miR-106a/b</td>
<td>Aβ peptides</td>
<td>Influence TGF-β signaling (76)</td>
<td>Increased firstly then decreased</td>
</tr>
<tr>
<td>miR-146a</td>
<td>Inflammation</td>
<td>Be detectable and involved in AD pathogenesis (70)</td>
<td>Decreased</td>
</tr>
<tr>
<td>miR-132</td>
<td>Tau proteins</td>
<td>Induce apoptosis (73) and accelerate Tau hyperphosphorylation (77)</td>
<td>Decreased (77)</td>
</tr>
<tr>
<td>miR-29a,29b</td>
<td>Aβ peptides</td>
<td>Influence the expression of APP and Tau (74,75)</td>
<td>Increased (75)</td>
</tr>
<tr>
<td>miR-107</td>
<td>Aβ peptides</td>
<td>Increase BACE1 mRNA levels (66)</td>
<td>Decreased</td>
</tr>
<tr>
<td>miR-9</td>
<td>Tau proteins</td>
<td>Influence the expression of Tau (75)</td>
<td></td>
</tr>
<tr>
<td>miR-124a</td>
<td>Aβ peptides</td>
<td>Alleviate neurodegeneration by targeting BACE1 (78)</td>
<td></td>
</tr>
<tr>
<td>miR-153</td>
<td>Aβ peptides</td>
<td>Inhibit expression of APP (79,80)</td>
<td>Decreased</td>
</tr>
</tbody>
</table>

TGF-β, transforming growth factor beta; Aβ, amyloid-β; APP, amyloid-β precursor protein; BACE1, β-site APP cleaving enzyme 1.

persons (81). One study in vitro demonstrated that apoE can facilitate the proteolytic degradation of Aβ in the brain (82). As is well known that ε4 allele of ApoE protein is less efficient in proteolysis of Aβ, thus increases the brain amyloid deposition in APOE ε4 allele carriers (83). Therefore, MCI subjects with the presence of APOE ε4 allele (ε4+ individuals) have higher CSF lipid-depleted Aβ (with great propensity for transformation to soluble Aβ oligomers) levels than ε4- individuals (84). While human apoE is complexed with Aβ, the clearance of Aβ across blood-brain barriers actually decreased compared to that of free Aβ (85).

Considering the strong effect of apoE alleles on the risk of developing AD, many studies have been conducted worldwide to investigate whether apoE protein levels are connected to AD. But, previous studies about CSF apoE levels in humans have yielded controversial results. One recent study found CSF ApoE levels weren’t associated with progression of AD (86). Maybe the concentrations of CSF apoE are not dramatically different between cognitively normal subjects and those with mild or moderate dementia. So researchers need more sensitive instruments or better innovation to differentiate AD cases from controls.

Other biomarkers

The conception of other pathways that may be associated with AD pathogenesis are pointed, such as the innate immune system, cholesterol metabolism and so on, although quantity of promising outcomes are obtained by the classical amyloid cascade hypothesis.

Some studies found CSF levels of YKL-40, a microglia (87) and astrocyte-derived (88) marker of neuroinflammation, were higher in preclinical and prodromal AD patients (89) and were tightly correlated with T-tau and P-tau levels (88,89). One study has shown microglial engagement in amyloid plaques with the capacity to prevent or reduce the formation of amyloid plaques in transgenic mice (90). In addition, microglial induced inflammatory processes are significantly associated with axonal degeneration and neuronal deficit in AD (91). Hence, the inflammation in this neurodegenerative disease is a double-edged sword, and it is more important to direct and instruct the inflammatory machinery than to suppress it.

Increasing evidence demonstrate that insulin resistance (IR) plays a critical role in Aβ production and accumulation (92,93), the Tau pathology (94), impaired synaptic transmission (95) and neuronal degeneration. IR could enhance β- and γ-secretase activity inducing Aβ production (93). One study demonstrated the utility of evaluating indices of IR and their consequences, i.e. oxidative stress, neuro-inflammation, and reduced neuronal plasticity combined with P-Tau and Aβ in CSF-based multiplex assays (96). IR can in the brain contribute to Aβ and tau pathology by means of oxidative stress and inflammation. In turn, Aβ accumulation can enhance IR through Aβ-mediated inflammation and oxidative stress. Additionally, hyperinsulinemia and hyperglycemia caused by IR accelerate also the formation of neuropathologic changes (97). Preclinical and clinical studies have supported
that insulin could be beneficial to the treatment of AD. Thus, the insulin level may be a novel biomarker in AD.

In a pilot study, Leoni et al. (98) found similar percentage and more sensitive of AD patients with increased levels of 24S-hydroxycholesterol than that of T-tau and P-tau demonstrated that 24OHC might be a valuable tool to boost the diagnostic performance of AD. More interesting novel biomarkers are proposed, such as Visinin-like protein-1 (99) which can serve as a good candidate for dynamic biomarker of AD and may play a role in the AD pathophysiology, Hydrogen peroxide-inducible clone 5 and paxillin (100) that make a difference in AD compared with controls, and glycogen synthase kinase 3β (101) coexisting with severe brain inflammation. Matrix metalloproteinases (MMPs) play multiple roles in the pathogenesis of AD (102), with MMP-2 being a protective factor, MMP-9 and MMP-3 being potential neurotoxic enzymes. The levels of plasma TNF-α converting enzyme activity correlated conspicuously and negatively with cognition in subjects with MCI and patients with AD (103). However, the majority of them are promising hypothesis-driven biomarkers, further studies are needed to support the role of these findings.

**The potential uses for body fluid biomarkers in clinical trials**

More and more potential uses for body fluid biomarkers in clinical trials were discovered with the development detection techniques. Besides in favor of early diagnosis, those biomarkers may be made full use of assessing disease progression, developing treatments, monitoring treatment effects. In an attempt to higher accuracy of early diagnosis, better prognosis and more safe and effective treatment effects, we should keep up striving.

**Improved early diagnosis**

Currently, to make a definite diagnosis of AD can only be based upon postmortem analysis of the brain. Early diagnosis for AD is a great limitation because of the paucity of specific symptoms in MCI cases. It is crucial and effective to get an early diagnosis biomarker to initiate or interfere with an adequate treatment in the early stages of the disorder. A multitude of studies have got the consistent findings that core CSF biomarkers, such as the Aβ42, T-tau and P-tau, can make a difference in preclinical or prodromal AD (104-106). The drop of CSF Aβ42 protein levels comes before the other CSF markers changes in preclinical AD (105). Gustafson et al. (107) have demonstrated that lowering of Aβ42 in CSF is a very early change in sporadic AD. Interesting, a previous study found tau pathology priors to amyloid plaque pathology (108). Further studies are needed to validate utility of AD biomarkers as a precise tool to differentiate patients with control participants in early phase of AD, since there may be a controversy for the choice of the appropriate biomarker.

Following scientists trend to have access to novel biomarkers so as to increase the accuracy of the clinical diagnosis of AD. Serum levels of Aβ peptides may be a valuable diagnosis marker (109), and the thioredoxin super family correlated proteins could involve in the pathogenesis of early AD as hopeful early diagnostic biomarkers (110). However, the well-known reliable predictive biomarkers, brain imaging and CSF measurement are expensive and invasive procedures respectively, and several candidate blood biomarkers with insufficiently sensitive or specific aren’t fully responsible for diagnosing early AD. Under the circumstances, the concept of “biomarker panels” is put forward to get over the great present challenge.

**Assessed disease progression**

Biomarkers may be used to assess disease progression to further stage early, middle, and advance AD pathogenesis event so as to guide clinical treatment. Many studies found biomarker magnitude enhance constantly with conversion from incipient stage to advanced AD. Accumulating evidence from both genetic at-risk individuals and clinically normal older cohorts suggests that the pathophysiologial process of AD begins 1 to 2 decades before the emergence of the clinical manifestation of dementia (111). In line with the preclinical period or prodromal stage refers to a progression that is progressing gradually towards cognitive deficit and behavioural impairment of AD. In consequence, the pathologic changes paid close attention to in early stage of AD contribute to the development of therapeutic interventions. Findings from Blennow et al. (112) suggested CSF levels of T-tau increased triple changes than control participants in developed AD.

It is clear, however, that some older individuals with the pathophysiologial process of AD may not become symptomatic during their whole lifetime. Thus, it is critical to better define a kind of biomarker that best predicts progression from the preclinical to the clinical stages of MCI and AD dementia so that the sufferers can benefit from early biomarker profile intervention.
Although limitations in view of the current lack of validated peripheral biomarkers, changes in peripheral biomarkers may be useful to differ from different stages of AD. A combination of central and peripheral biomarkers could be developed to help to stage AD, and the role of biomarkers in improving the accuracy of this prediction awaits results of future studies.

**Developed treatments**

Neurologist and psychiatrist have hungered for potential disease modifying effects, a novel AD therapy, which the scientists are exploring strenuously to prevent or attenuate the progression of AD effectively.

Since Aβ is thought to be a central pathogenic culprit, the disease-modifying therapy is being established, especially inhibitors of Aβ-producing proteases and Aβ immunotherapy which are now considered as prophylaxis for patients with MCI. In a cell culture model study, six novel compounds reducing expression of APP resulting in decreased Aβ-levels provide valuable information for the development of Aβ-modifying therapies for AD (113). Additionally, therapeutic intervention used an anti-Aβ-oligomers antibody benefits for neuronal protection by Aβ aggregation pathway in AD (114). BACE1 inhibitors, as an indirect depressors of Aβ by lowering or reducing CSF Aβ levels, progressed into Phase 1 clinical trials in humans (115). Another novel potential biomarker associated with amyloid-modifying therapies is anti-Aβ autoantibodies (116). Lemere et al. (117) suggested the shorter Aβ immunogens might induce the higher titers of antibodies that was able to clear cerebral Aβ and they could serve as a safer vaccine to prevent and treat AD patients optimistically. Of course, blood biomarker tests may be useful in clinical trials of treatment for AD. But, the findings are still under debate due to obvious advantages or disadvantages.

Current approaches including anti-Aβ disease-modifying drugs, cholinesterase inhibitors and N-methyl-d-aspartate receptor antagonists, are symptomatic treatments for AD, and do not cut off disease progression. Both laboratory data and recent disappointing clinical trial results raise the possibility that therapeutic interventions applied earlier in the course of AD would be more probable to achieve disease modification. In other words, Aβ-modifying therapies may have limited effect if pathophysiological process of AD has begun. One recent clinical trial regarding late-stage drug development for AD shown that 95% drug development has failed to demonstrate clinical effects, even in the setting of biomarker or autopsy evidence of decreased Aβ levels (118). Opinions from secondary prevention studies suggest therapeutic interventions against asymptomatic individuals or those with subtle evidence of impairment due to AD can postpone the onset of advanced clinical manifestation. So, before significant cognitive impairment or memory loss, in the “presymptomatic” or “preclinical” stages of AD, patients would be optimally treated. Many researchers in the field suggest that a possible strategy to achieve success is earlier intervention. To delay or prevent later neurodegeneration and eventual dementia, further preclinical studies are needed to find an appropriate treatment.

What appears to be well understood is that AD is a heterogeneous disorder, at both the clinical and neuropathological levels (119). As mentioned above, the effects of disease modifying drugs will differ between subgroups of AD patients in the case of degree of plaque and tangle pathology. It is sufficient to consider desirable to stratify the patient cohort in AD clinical trials based on disease progression, which may show the better effect of anti-Aβ disease-modifying drugs in lower levels of CSF Aβ42 subjects than a normal subgroup.

**Monitored treatment effects**

Biomarkers well known as “theragnostic markers” are used to identify and monitor the biochemical effect of drugs (106). Although disease modifying therapies can delay progression, improve the lives of patients and prolong their period of relatively good, non-disabled life, great importance should be attached to off-target or adverse effects of treatment. For example, both active and passive immunization strategies have been investigated to increase the clearance of Aβ. However, meningoencephalitis was observed in a subset of cases with mild to moderate AD in the aggregated Aβ42 with a QS-21 adjuvant (AN1792) trial on active Aβ immunotherapy (120), leading to development of AN1792 discontinuing. Passive immunization strategies may cause local microglial activation, of which side effects including microhemorrhage and vasogenic edema also reported were associated with patients particularly carrying the ApoE e4 allele.

Of course, much attention should be paid to positive and available biochemical effect of drugs. For instance, cholinesterase inhibitors are drugs expected to an early improvement in cognitive function. Instead of an early effect on symptoms, disease-modifying drugs will lead to
a less remarkable decline in cognitive function over years by retarding or ultimately even preventing the onset of cognitive impairment and dementia. Two studies found that infusion of solanezumab, an anti-β-amyloid antibody, was generally well tolerated in patients with mild-to-moderate AD (121,122). Therefore, it is meaningful to monitor this medicine treatment effects continually.

**Challenges in validation and application of AD biomarkers to clinical practice**

Although the number of AD biomarkers in discovery is enormous, those in clinical application are substantially low. The imperfect biomarkers may have a limit effect on clinical trials or practices. The overlap in pathology suggested a small proportion of individuals who are classified as stage 0 are probably experiencing early AD processes that detectable in advanced stage. Recent longitudinal data suggest that each year, approximately 3% of clinically normal individuals cross the threshold from “amyloid-negative” to “amyloid-positive” on PET imaging (123). The better biomarkers can stratify AD patients more distinctly, which can lead to more effective treatment, and simultaneously avoid unwanted misdiagnoses.

Since the most of AD biomarker chemical properties are proteins, it’s comprehensible that Preanalytical variations are also important factors including sample collection conditions, timing of sample processing and sample storage conditions. Besides a poor study design that does not address the specific research questions, other potential important factors in regard to study design contain heterogeneity in the inclusion of patients and controls, a lack of prospective studies or validation cohorts, insufficient sample size, and a paucity of confirmation of findings with different techniques.

Another challenge is the scarcity of assay standardization, especially the stringency of the statistical analyses. Different researchers employed different experimental techniques and methods, and gave different absolute concentrations of the protein, which led younger generation to state the difficulties in the discovery of candidate biomarkers. Combination of strict statistical criteria with biological criteria might be expected to help clinicians to focus on novel biomarkers with the most potential for validation.

Although plasma sampling is much easier, with fewer side effects, and is readily applied in primary care centers, two problems exist with limitation of utility of the plasma markers. One problem is that CSF undergoes substantial dilution as it passages into the bloodstream due to the blood-brain barrier, and this raises challenges in trying to detect brain-specific biomarkers in plasma—their concentration is likely to be orders of magnitude lower than in the brain or CSF. Another problem is that changes in the blood reflect more from the systemic effects rather than specific brain changes in AD, which bring about the lower specificity.

The low specificity and sensitivity of current biomarkers hamper the application of them in clinical practice. Some validated biomarkers are not specific for AD, for example, P-tau and T-tau can also over express in normal aging, other chronic brain injury, amyotrophic lateral sclerosis (124,125), Creutzfeldt-Jakob disease (126), Parkinson’s disease (127), epileptic seizures (128) and even breast cancer (129) and so on; similarly, the lower Aβ levels can also be detectable in other dementias and cardiac arrest survivors (130). Unfriendly physiopathologic overlaps between vascular dementia and AD create the limitation of the study design even with neuroimaging (131). It is impossible to exclude all the subjects with vascular brain injury, so most of the AD group also contains patients with vascular abnormalities.

**What is the ideal biomarker in AD?**

The ideal biomarker in AD should present in patients with AD and absent in healthy individuals or those with other pathological disorders, and levels would increase or decrease when the disease worsens or improves, respectively. Some other desired properties of molecular biomarkers for AD should be also considered in addition to this theoretical and simple scenario. In brief, the marker must have a scientific rationale, the marker must be measurable and reproducible, the marker must be specific for AD and the biomarker should change with disease progression in longitudinal observational studies. The ideal biomarker should give clinicians no other alternative than to rely on clinical diagnosis by exclusion. The category of biomarkers for diagnosis should be strongly associated with onset of AD, and suggest diagnoses with no false positive or negative results presymptomatically. With the development of AD pathophysiological processes, the levels of disease activity biomarkers should have obvious changes over time, and with respect to treatment-response biomarkers, to monitor or capture absolutely the effect of treatment would be crucial (Table 2).
Future perspectives of biomarker studies

The use of criteria for sample collection and storage conditions as well as timing of sample processing will be crucial to scientific researches regarding discovery and validation of biomarkers in large cohorts of patients with AD. AD is a heterogeneous disease, with many different treatments giving rise to numerous debates how to give the proper treatment to the right patient. So, it is essential that treatment-response biomarkers need to identify accurately individuals with a high risk of adverse effects as well as predict precisely the responder or nonresponder, and tolerated or untolerated status of patients. Nevertheless, consistent standards of the definitions of treatment response or not have not yet reached. In addition, a better design in treatment-response study is needed, since studies do not allow for difference between natural progression and true treatment response.

Lumbar puncture employed in the collection of CSF is an invasive procedure that limits repeated collection and its use in clinical practice can be in trouble. Well accessible body fluids (including peripheral blood, urine, saliva) less invasively collected than CSF, which seems be in favour of the use of blood-borne biomarkers or biomarkers derived other body fluids in AD clinical practice. However, the dilution of the concentration caused by the effect of blood-brain barrier restricts the process of clinical trials. Further investigation is needed to verify utilities of other body fluid biomarkers excluding CSF.

Combination of multiple biomarker modalities including various body fluids biomarkers, both structural (CT/MRI) and functional (SPECT/PET) brain imaging will improve the diagnostic accuracy as compared with the use of one biomarker alone. Vemuri et al. found that the combination of positive CSF biomarkers and MRI with clinical diagnosis, providing complementary information, increased the chance to predict the conversion from amnestic MCI to AD better than either source of data alone (132). With a high sensitivity and specificity to identify AD patients from controls attributed to the combined data on plasma TNF-α receptors signaling proteins, Aβ and the APOEε4 allele (133). One study about the combination of neuropsychological and biological markers in AD suggested that this biomarker panel could be used as a new tool to track disease progression in early AD as well as the response to disease-modifying drugs (134). To further validate the improved diagnostic and treatment-response value of combining multiple biomarkers need more multicenter studies.

Conclusions

The predecessor have implemented enormous amounts of studies about CSF AD biomarkers and procured plentiful and substantial progeny. In addition, novel biomarkers are recommended as the noninvasive markers playing an important role in the future studies in AD. We have unprecedented possibilities to be able to stratify our patients, improve diagnosis early, monitor progression and optimize treatment with the development of body fluid biomarkers. However, the mechanism of onset of AD has been unknown, to capture the conversion from undementia to dementia and the most appropriate or ideal biomarkers will be a strongly challenge in further studies.

Acknowledgements

Funding: This work was supported by grants from the National Natural Science Foundation of China (81471309, 81171209), the Shandong Provincial Outstanding Medical Academic Professional Program, Qingdao Key Health Discipline Development Fund, Qingdao Outstanding Health Professional Development Fund, and Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders.

Disclosure: The authors declare no conflict of interest.

References

58. Chiu MJ, Chen YF, Chen TF, et al. Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early


apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol 2013;70:972-80.


